LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Yutaka, TSUTSUMI; Yasuyuki, KOMATSU; Nobuo, MASAUZI (2008)
Publisher: 市立函館病院
Journal: 函館医学誌 = Hakodate medical journal
Languages: English
Types: Article
Subjects: Multiple myeloma(MM), myelomatous pleural effusion, kappa and lambda, Durie and Salmom classification, renal dysfunction
We reported a patient with multiple myeloma who developed myelomatous pleural effusion (MPE). This patient had nine courses of chemotherapy, and pleural effusion developed after the fourth course. Although administration of several chemotherapeutic agents and intrapleural administration of OK432 were performed, the patient died 4 months after the development of MPE. We analyzed the previous reports to clarify the characteristics of patients who developed MPE.

Share - Bookmark

Download from

Cite this article

Collected from

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok